Harald Holte

Publications by Harald H. Holte

151 publications found

Publications in press

1. Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg A, Hjalmarsson E, Holte H, Ostenstad B, Brown PD, Smeland EB, Kimby E
   Higher WHO grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy
   Leuk Lymphoma (in press)
   PubMed 23662992
2. Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H
   Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
   Leuk Lymphoma (in press)
   PubMed 23391141

Publications 2013

1. Dörffel W, Rühl U, Lüders H, Claviez A, Albrecht M, Bökkerink J, Holte H, Karlen J, Mann G, Marciniak H, Niggli F, Schmiegelow K, Schwarze EW, Pötter R, Wickmann L, Schellong G (2013)
   Treatment of Children and Adolescents With Hodgkin Lymphoma Without Radiotherapy for Patients in Complete Remission After Chemotherapy: Final Results of the Multinational Trial GPOH-HD95
   J Clin Oncol, 31 (12), 1562-8
   PubMed 23509321
2. Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A (2013)
   Enhancement characteristics of retroperitoneal lymphomatous lymph nodes
   Acta Radiol, 54 (3), 333-9
   PubMed 23446747
3. Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M (2013)
   Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
   Ann Oncol, 24 (5), 1385-92
   PubMed 23247661

Publications 2012

1. d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE (2012)
   Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
   J Clin Oncol, 30 (25), 3093-9
   PubMed 22851556
2. Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE, Dybedal I, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen GF, Fosså A, Lehne G, Baggerød E, Kvalheim G, Egeland T, Bishop MR, Fowler DH, Kolstad A (2012)
   Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation
   Bone Marrow Transplant, 47 (12), 1552-7
   PubMed 22522568
3. Fosså A, Fiskvik IH, Kolstad A, Lauritzsen GF, Aurlien E, Blystad AK, Hole KH, Ikonomou IM, Holte H (2012)
   Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis
   Ann Oncol, 23 (5), 1254-9
   PubMed 21926399
4. Mitrovic Z, Perry AM, Suzumiya J, Armitage JO, Au WY, Coiffier B, Holte H, Jaffe ES, Monserrat E, Rajan SK, Savage KJ, Tobinai K, Vose JM, Weisenburger DD (2012)
   The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma Project
   Am J Hematol, 87 (8), 790-4
   PubMed 22488678
5. Riihijärvi S, Nurmi H, Holte H, Björkholm M, Fluge O, Pedersen LM, Rydström K, Jerkeman M, Eriksson M, Leppä S (2012)
   High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy
   Eur J Haematol, 89 (5), 395-402
   PubMed 22882209
6. Torfoss D, Høiby EA, Holte H, Kvaløy S (2012)
   The Norwegian experience with penicillin G plus an aminoglycoside as initial empiric therapy in febrile neutropenia; a review
   Acta Oncol, 51 (4), 433-40
   PubMed 22175253
7. Wahlin BE, Sander B, Christensson B, Ostenstad B, Holte H, Brown PD, Sundström C, Kimby E (2012)
   Entourage: the immune microenvironment following follicular lymphoma
   Blood Cancer J, 2 (1), e52
   PubMed 22829236
8. Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundström C, Christensson B, Sander B (2012)
   Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
   Br J Haematol, 156 (2), 225-33
   PubMed 22126847
9. Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2012)
   Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma
   Leuk Lymphoma, 53 (10), 1934-44
   PubMed 22475179

Publications 2011

1. Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ, Connors JM, Rimsza L, Harris NL, Müller-Hermelink K, Rüdiger T, Coiffier B, Gascoyne RD, Berger F, Tobinai K, Au WY, Liang R, Montserrat E, Hochberg EP, Pileri S, Federico M, Nathwani B, Armitage JO, Weisenburger DD (2011)
   Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project
   Blood, 118 (1), 148-55
   PubMed 21566094
2. Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H (2011)
   High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study
   Br J Haematol, 152 (5), 600-10
   PubMed 21241276
3. Grotmol T, Bray F, Holte H, Haugen M, Kunz L, Tretli S, Aalen OO, Moger TA (2011)
   Frailty modeling of the bimodal age-incidence of Hodgkin lymphoma in the Nordic countries
   Cancer Epidemiol Biomarkers Prev, 20 (7), 1350-7
   PubMed 21558495
4. Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A (2011)
   Enhancement characteristics of lymphomatous lymph nodes of the mediastinum
   Acta Radiol, 52 (10), 1113-8
   PubMed 22052959
5. Torfoss D, Sandstad B, Mollnes TE, Høiby EA, Holte H, Bjerner J, Bjøro T, Gaudernack G, Kvalheim G, Kvaløy S (2011)
   The mild inflammatory response in febrile neutropenic lymphoma patients with low risk of complications is more pronounced in patients receiving tobramycin once daily compared with three times daily
   Scand J Immunol, 74 (6), 632-9
   PubMed 21883353
6. Wahlin BE, Sundström C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenhölder M, Tierens AM, Sander B, Christensson B, Kimby E (2011)
   T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab
   Clin Cancer Res, 17 (12), 4136-44
   PubMed 21518780
7. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM, International Peripheral T-cell Lymphoma Project (2011)
   Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
   Blood, 117 (12), 3402-8
   PubMed 21270441

Publications 2010

1. Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010)
   Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
   Blood, 116 (9), 1489-97
   PubMed 20505157
2. Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A (2010)
   Enhancement characteristics of lymphomatous lymph nodes of the neck
   Acta Radiol, 51 (5), 555-62
   PubMed 20429760
3. Kiserud CE, Loge JH, Fosså A, Holte H, Cvancarova M, Fosså SD (2010)
   Mortality is persistently increased in Hodgkin's lymphoma survivors
   Eur J Cancer, 46 (9), 1632-9
   PubMed 20219350
4. Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M (2010)
   Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL
   Br J Haematol, 149 (2), 237-43
   PubMed 20201949
5. Ruland CM, Holte HH, Røislien J, Heaven C, Hamilton GA, Kristiansen J, Sandbaek H, Kvaløy SO, Hasund L, Ellison MC (2010)
   Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients' need for symptom management support: a randomized clinical trial
   J Am Med Inform Assoc, 17 (4), 403-10
   PubMed 20595307
6. Tauro S, Cochrane L, Lauritzsen GF, Baker L, Delabie J, Roberts C, Mahendra P, Holte H (2010)
   Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols
   Am J Hematol, 85 (4), 261-3
   PubMed 20201088
7. Tierens AM, Holte H, Warsame A, Ikonomou IM, Wang J, Chan WC, Delabie J (2010)
   Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type
   Haematologica, 95 (8), 1334-41
   PubMed 20145271
8. van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA (2010)
   BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study
   J Clin Oncol, 28 (13), 2246-52
   PubMed 20368567
9. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A (2010)
   Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study
   J Clin Oncol, 28 (17), 2853-8
   PubMed 20439641
10. van Oers MHJ, Tonnissen E, van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA (2010)
    Prognostic Significance of Molecular Remission in Follicular Lymphoma Reply
    J. Clin. Oncol., 28 (30), E614

Publications 2009

1. Holte H, Kvaløy S, Delabie J, Trøen G, Smeland EB (2009)
   [Molecular diagnosis of malignant lymphomas]
   Tidsskr Nor Laegeforen, 129 (22), 2352-6
   PubMed 19935935
2. Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW (2009)
   Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens
   Clin Lymphoma Myeloma, 9 (4), 307-10
   PubMed 19717381
3. Kiserud CE, Fosså A, Bjøro T, Holte H, Cvancarova M, Fosså SD (2009)
   Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy
   Br J Cancer, 100 (3), 455-63
   PubMed 19156143
4. Kiserud CE, Schover LR, Dahl AA, Fosså A, Bjøro T, Loge JH, Holte H, Yuan Y, Fosså SD (2009)
   Do male lymphoma survivors have impaired sexual function?
   J Clin Oncol, 27 (35), 6019-26
   PubMed 19858388
5. O'Shea D, O'Riain C, Gupta M, Waters R, Yang Y, Wrench D, Gribben J, Rosenwald A, Ott G, Rimsza LM, Holte H, Cazier JB, Johnson NA, Campo E, Chan WC, Gascoyne RD, Young BD, Staudt LM, Lister TA, Fitzgibbon J (2009)
   Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation
   Blood, 113 (10), 2298-301
   PubMed 19141865
6. Wethal T, Lund MB, Edvardsen T, Fosså SD, Pripp AH, Holte H, Kjekshus J, Fosså A (2009)
   Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study
   Br J Cancer, 101 (4), 575-81
   PubMed 19623176

Publications 2008

1. Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Lindén O, Sundström C, Nordic Lymphoma Group (2008)
   Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group
   Leuk Lymphoma, 49 (1), 102-12
   PubMed 18203019
2. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G et al. (2008)
   Stromal gene signatures in large-B-cell lymphomas
   N Engl J Med, 359 (22), 2313-23
   PubMed 19038878
3. Torfoss D, Høiby EA, Holte H, Kvaløy S (2008)
   [Penicillin and aminoglycoside in febrile neutropenia]
   Tidsskr Nor Laegeforen, 128 (23), 2738-40
   PubMed 19079423

Publications 2007

1. Björkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Ståhl E, Myhre J, Pertovaara H, Ost A, Nilsson B, Osby E (2007)
   Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up
   Ann Oncol, 18 (6), 1085-9
   PubMed 17363838
2. Kiserud CE, Fosså A, Holte H, Fosså SD (2007)
   Post-treatment parenthood in Hodgkin's lymphoma survivors
   Br J Cancer, 96 (9), 1442-9
   PubMed 17406362
3. Kolstad A, Holte H, Fosså A, Lauritzsen GF, Gaustad P, Torfoss D (2007)
   Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen
   Haematologica, 92 (1), 139-40
   PubMed 17229653
4. Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H (2007)
   Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma
   Leuk Lymphoma, 48 (3), 570-6
   PubMed 17454601
5. Oldervoll LM, Loge JH, Kaasa S, Lydersen S, Hjermstad MJ, Thorsen L, Holte H, Jacobsen AB, Fosså SD (2007)
   Physical activity in Hodgkin's lymphoma survivors with and without chronic fatigue compared with the general population - a cross-sectional study
   BMC Cancer, 7, 210
   PubMed 17997822
6. Torfoss D, Høiby EA, Tangen JM, Holte H, Bø K, Meyer P, Grøttum K, Weyde K, Lauritzsen GF, Sandstad B, Jacobsen AB, Olsen H, Kvaløy S (2007)
   Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial
   J Antimicrob Chemother, 59 (4), 711-7
   PubMed 17327294
7. Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI et al. (2007)
   Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
   Blood, 109 (11), 4599-606
   PubMed 17299095
8. Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Bergh J (2007)
   Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
   Ann Oncol, 18 (4), 694-700
   PubMed 17301072
9. Aamot HV, Torlakovic EE, Eide MB, Holte H, Heim S (2007)
   Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic-pathologic-clinical correlations
   J Cancer Res Clin Oncol, 133 (7), 455-70
   PubMed 17235551

Publications 2006

1. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB et al. (2006)
   Molecular diagnosis of Burkitt's lymphoma
   N Engl J Med, 354 (23), 2431-42
   PubMed 16760443
2. Haukvik UK, Dieset I, Bjøro T, Holte H, Fosså SD (2006)
   Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma
   Ann Oncol, 17 (9), 1428-33
   PubMed 16831852
3. Hjermstad MJ, Hollender A, Warloe T, Karlsen KO, Ikonomo I, Kvaloy S, Nome O, Holte H (2006)
   Quality of life after total or partial gastrectomy for primary gastric lymphoma
   Acta Oncol, 45 (2), 202-9
   PubMed 16546867
4. Hjermstad MJ, Oldervoll L, Fosså SD, Holte H, Jacobsen AB, Loge JH (2006)
   Quality of life in long-term Hodgkin's disease survivors with chronic fatigue
   Eur J Cancer, 42 (3), 327-33
   PubMed 16377179
5. Hollender A, Bjøro T, Otto Karlsen K, Kvaloy SO, Nome O, Holte H (2006)
   Vitamin D deficiency in patients operated on for gastric lymphoma
   Scand J Gastroenterol, 41 (6), 673-81
   PubMed 16716965
6. Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, Patzke S, Smeland EB, Stokke T (2006)
   Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
   Leukemia, 20 (3), 539-42
   PubMed 16437153
7. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A (2006)
   Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
   Blood, 108 (10), 3295-301
   PubMed 16873669

Publications 2005

1. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R et al. (2005)
   Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
   Blood, 106 (9), 3183-90
   PubMed 16046532
2. Fosså SD, Holte H, Holmen MM, Bjøro T, Langmark F, Hess SL, Kvaløy S (2005)
   [Long-term effects after mantle field radiotherapy for Hodgkin's lymphoma]
   Tidsskr Nor Laegeforen, 125 (1), 41-4
   PubMed 15643464
3. Hjermstad MJ, Fosså SD, Oldervoll L, Holte H, Jacobsen AB, Loge JH (2005)
   Fatigue in long-term Hodgkin's Disease survivors: a follow-up study
   J Clin Oncol, 23 (27), 6587-95
   PubMed 16170166
4. Aamot HV, Micci F, Holte H, Delabie J, Heim S (2005)
   G-banding and molecular cytogenetic analyses of marginal zone lymphoma
   Br J Haematol, 130 (6), 890-901
   PubMed 16156859

Publications 2004

1. Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I, Kvalheim G (2004)
   Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy
   Br J Haematol, 125 (5), 605-12
   PubMed 15147376
2. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA et al. (2004)
   Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
   N Engl J Med, 351 (21), 2159-69
   PubMed 15548776
3. Hjermstad MJ, Knobel H, Brinch L, Fayers PM, Loge JH, Holte H, Kaasa S (2004)
   A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation
   Bone Marrow Transplant, 34 (3), 257-66
   PubMed 15170167
4. Jerkeman M, Leppä S, Kvaløy S, Holte H (2004)
   ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience
   Eur J Haematol, 73 (3), 179-82
   PubMed 15287915
5. Kolstad A, Risberg T, Bremnes Y, Wilsgaard T, Holte H, Klepp O, Mella O, Wist E (2004)
   Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway
   Support Care Cancer, 12 (5), 312-8
   PubMed 14767750
6. Nermoen I, Foss A, Holte H, Mathisen Ø, Brekke IB, Line PD, Bergan A (2004)
   [Surgical treatment of hormone-producing adrenocortical carcinoma with liver metastases]
   Tidsskr Nor Laegeforen, 124 (23), 3061-3
   PubMed 15586188
7. Risberg T, Bremnes Y, Kolstad A, Holte H, Wist E, Mella O, Klepp O (2004)
   [Should complementary therapies be offered in hospitals?]
   Tidsskr Nor Laegeforen, 124 (23), 3078-80
   PubMed 15586193
8. Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR (2004)
   Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway
   Eur J Cancer, 40 (4), 529-35
   PubMed 14962719
9. Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrøm J, Lauritzsen GF, Holte H (2004)
   Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens
   Ann Oncol, 15 (7), 1072-8
   PubMed 15205201

Publications 2003

1. Osby E, Hagberg H, Kvaløy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Holte H, Myhre J, Pertovaara H, Björkholm M, Nordic Lymphoma Group (2003)
   CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
   Blood, 101 (10), 3840-8
   PubMed 12531794
2. Risberg T, Kolstad A, Wist EA, Holte H, Mella O, Klepp O (2003)
   [Should alternative therapists treat cancer--what is the opinion of oncology health personnel?]
   Tidsskr Nor Laegeforen, 123 (21), 3059-61
   PubMed 14618177
3. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R et al. (2003)
   Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
   J Exp Med, 198 (6), 851-62
   PubMed 12975453
4. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC et al. (2003)
   The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
   Cancer Cell, 3 (2), 185-97
   PubMed 12620412

Publications 2002

1. Abrahamsen AF, Andersen A, Nome O, Jacobsen AB, Holte H, Abrahamsen JF, Kvaloy S (2002)
   Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time
   Ann. Oncol., 13 (11), 1786-1791
2. Foss Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaløy S (2002)
   Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time
   Ann Oncol, 13 (11), 1786-91
   PubMed 12419752
3. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H (2002)
   Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model
   Ann Oncol, 13 (7), 1099-107
   PubMed 12176790
4. Holte H, Smeland S, Blystad AK, Kvaløy S, Hammerstrøm J, Tjønnfjord GE (2002)
   [Intensive chemotherapy in Burkitt's lymphoma and aggressive non-Hodgkin's lymphoma]
   Tidsskr Nor Laegeforen, 122 (4), 364-9
   PubMed 11915663
5. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ et al. (2002)
   The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
   N Engl J Med, 346 (25), 1937-47
   PubMed 12075054
6. Aamot H, Micci F, Holte H, Delabie J, Heim S (2002)
   M-FISH cytogenetic analysis of non-Hodgkin lymphomas with t(14;18)(q32;q21) and add(1)(p36) as a secondary abnormality shows that the extra material often comes from chromosome arm 17q
   Leuk Lymphoma, 43 (5), 1051-6
   PubMed 12148885

Publications 2001

1. Aurlien E, Holte H, Kvaloy S, Jakobsen E, Rusten LS, Kvalheim G (2001)
   Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients
   Eur. J. Haematol., 66 64, 14-20
2. Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G (2001)
   Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients
   Eur J Haematol Suppl, 64, 14-20
   PubMed 11486395
3. Blystad AK, Enblad G, Kvaløy S, Berglund A, Delabie J, Holte H, Carlson K, Kvalheim G, Bengtsson M, Hagberg H (2001)
   High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas
   Bone Marrow Transplant, 27 (7), 711-6
   PubMed 11360110
4. Blystad AK, Holte H, Kvaløy S, Smeland E, Delabie J, Kvalheim G (2001)
   High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells
   Bone Marrow Transplant, 28 (9), 849-57
   PubMed 11781645
5. Blystad AK, Torlakovic E, Holte H, Kvaløy S, Lenschow E, Kvalheim G (2001)
   CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD
   Cytotherapy, 3 (4), 295-305
   PubMed 12171718
6. Hall KS, Wiklund T, Erikstein B, Holte H, Kvalheim G, Sommer HH, Andersen A, Skovlund E, Bergh J, Hall C (2001)
   Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients
   Breast Cancer Res Treat, 67 (3), 235-44
   PubMed 11561769
7. Holte HH, Tambs K, Bjerkedal T (2001)
   Becoming a disability pensioner with rheumatoid arthritis in Norway 1971-1990
   J Rheumatol, 28 (1), 54-61
   PubMed 11196543
8. Nordøy T, Husebekk A, Aaberge IS, Jenum PA, Samdal HH, Flugsrud LB, Kristoffersen AC, Holte H, Kvaløy S, Kolstad A (2001)
   Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines
   Bone Marrow Transplant, 28 (7), 681-7
   PubMed 11704791
9. Stokke T, DeAngelis P, Smedshammer L, Galteland E, Steen HB, Smeland EB, Delabie J, Holte H (2001)
   Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma
   Br J Cancer, 85 (12), 1900-13
   PubMed 11747333
10. Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH (2001)
    High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group
    J Clin Oncol, 19 (11), 2927-36
    PubMed 11387366

Publications 2000

1. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000)
   Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study
   Lancet, 356 (9239), 1384-91
   PubMed 11052580
2. Hagen KB, Holte HH, Tambs K, Bjerkedal T (2000)
   Socioeconomic factors and disability retirement from back pain: a 1983-1993 population-based prospective study in Norway
   Spine (Phila Pa 1976), 25 (19), 2480-7
   PubMed 11013500
3. Hollender A, Kvaloy S, Lote K, Nome O, Holte H (2000)
   Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis
   Eur J Cancer, 36 (14), 1762-8
   PubMed 10974623
4. Holte HH, Tambs K, Bjerkedal T (2000)
   Manual work as predictor for disability pensioning with osteoarthritis among the employed in Norway 1971-1990
   Int J Epidemiol, 29 (3), 487-94
   PubMed 10869321
5. Lote K, Holte H, Kvaloy S (2000)
   Testicular lymphoma is associated with a high risk of extranodal recurrence
   Cancer, 89 (3), 713-4
   PubMed 10931479
6. Lote K, Holte H, Nome O, Langholm R, Kvaløy S (2000)
   Stage I high-grade non-Hodgkin's lymphoma
   Acta Oncol, 39 (7), 865-72
   PubMed 11145446
7. Stokke T, Galteland E, Holte H, Smedshammer L, Suo Z, Smeland EB, Børresen-Dale AL, DeAngelis P, Steen HB (2000)
   Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma
   Int J Cancer, 89 (4), 313-24
   PubMed 10956404

Publications 1999

1. Abrahamsen AF, Loge JH, Hannisdal E, Nome O, Lund MB, Holte H, Kvaløy S (1999)
   Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease
   Acta Oncol, 38 (4), 511-5
   PubMed 10418720
2. Andersen A, Holte H, Slørdal L (1999)
   Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients
   Cancer Chemother Pharmacol, 44 (5), 422-6
   PubMed 10501917
3. Blystad A, Kvalheim G, Torlakovic E, Holte H, Jacobsen E, Beiske K, Vâlerhaugen H, Lenschow E, Kvaloy S (1999)
   High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma
   Bone Marrow Transplant, 24 (8), 865-72
   PubMed 10516698
4. Galteland E, Holte H, Stokke T (1999)
   c-MYC, RB-1, TP53, and centromere 8 and 17 copy number in B-cell non-Hodgkin's lymphomas assessed by dual-color fluorescence in situ hybridization
   Cytometry, 38 (2), 53-60
   PubMed 10323217
5. Hjermstad M, Holte H, Evensen S, Fayers P, Kaasa S (1999)
   Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year?
   Bone Marrow Transplant, 24 (8), 911-8
   PubMed 10516705
6. Holte H, Suo Z, Smeland EB, Kvaløy S, Langholm R, Stokke T (1999)
   Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers
   Acta Oncol, 38 (4), 495-503
   PubMed 10418718
7. Lindman H, Wiklund T, Holte H, Ljungman P, Blomqvist C, Kvalheim G, Bengtsson M, Höglund M, Wilking N, Bergh J (1999)
   FEC mobilized stem cells for high-dose therapy in breast cancer patients. SB6 9401 Study Group
   Acta Oncol, 38 (2), 239-45
   PubMed 10227447
8. Nordøy T, Kolstad A, Endresen P, Holte H, Kvaløy S, Kvalheim G, Husebekk A (1999)
   Persistent changes in the immune system 4-10 years after ABMT
   Bone Marrow Transplant, 24 (8), 873-8
   PubMed 10516699

Publications 1998

1. Abrahamsen AF, Loge JH, Hannisdal E, Holte H, Kvaløy S (1998)
   Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution
   Eur J Cancer, 34 (12), 1865-70
   PubMed 10023307
2. Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G (1998)
   Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma
   Bone Marrow Transplant, 21 (9), 873-8
   PubMed 9613778
3. Galteland E, Sivertsen EA, Lote K, Holte H, Kvaløy S (1998)
   [Primary non-Hodgkin's lymphoma of the brain]
   Tidsskr Nor Laegeforen, 118 (29), 4524-6
   PubMed 9889638
4. Stokke T, Holte H, Smedshammer L, Smeland EB, Kaalhus O, Steen HB (1998)
   Proliferation and apoptosis in malignant and normal cells in B-cell non-Hodgkin's lymphomas
   Br J Cancer, 77 (11), 1832-8
   PubMed 9667654
5. Stokke T, Smeland EB, Kvaløy S, Holte H (1998)
   Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas
   Br J Cancer, 77 (11), 1839-41
   PubMed 9667655

Publications 1997

1. Abrahamsen AF, Egeland T, Hansen S, Langholm R, Holte H, Kvaloy S (1997)
   Hodgkin's disease in a national and hospital population: Trends over 20 years
   Eur. J. Cancer, 33 (14), 2380-2383
2. Abrahamsen AF, Hoiby EA, Hannisdal E, Jorgensen OG, Holte H, Hasseltvedt V, Host H (1997)
   Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: A follow-up study 1994
   Eur. J. Haematol., 58 (2), 73-77
3. Foss Abrahamsen A, Egeland T, Hansen S, Langholm R, Holte H, Kvaløy S (1997)
   Hodgkin's disease in a national and hospital population: trends over 20 years
   Eur J Cancer, 33 (14), 2380-3
   PubMed 9616285
4. Foss Abrahamsen A, Høiby EA, Hannisdal E, Jørgensen OG, Holte H, Hasseltvedt V, Høst H (1997)
   Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: a follow-up study 1994
   Eur J Haematol, 58 (2), 73-7
   PubMed 9111586
5. Lien HH, Blomlie V, Blystad AK, Holte H, Langholm R, Kvaløy S (1997)
   Bone-marrow MR imaging before and after autologous marrow transplantation in lymphoma patients without known bone-marrow involvement
   Acta Radiol, 38 (5), 896-902
   PubMed 9332252

Publications 1996

1. Abrahamsen AF, Hannisdal E, Nome O, Elgio RF, Holte H, Hager B, Langholm R, Kvaløy S (1996)
   Prognostic variables and results of salvage treatment in Hodgkin's disease
   Acta Oncol, 35 Suppl 8, 67-72
   PubMed 9073050
2. Abrahamsen AF, Hannisdal E, Nome O, Holte H, Hager B, Langholm R, Kvaløy S (1996)
   Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution
   Ann Oncol, 7 (2), 145-50
   PubMed 8777170
3. Holte H, Kvaløy SO, Engan T, Evensen SA, Mella O, Tangen JM, Wesenberg F, Wist EA (1996)
   [High dose therapy with autologous stem cell support in malignant disorders. Excerpt from the statement by the advisory group of the State Health Services]
   Tidsskr Nor Laegeforen, 116 (21), 2577-81
   PubMed 8928130
4. Holte H, Mella O, Wist E, Telhaug R, Hannisdal E, Abrahamsen AF (1996)
   ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease
   Acta Oncol, 35 Suppl 8, 73-80
   PubMed 9073051
5. Kolstad A, Holte H, Kvaløy S, Jakobsen E, Erikstein B, Aurlien E, Kvalheim G, Bøhler PJ, Langholm R (1996)
   [High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood]
   Tidsskr Nor Laegeforen, 116 (21), 2547-51
   PubMed 8928122
6. Kvalheim G, Holte H, Jakobsen E, Kvaloy S (1996)
   Immunomagnetic purging of lymphoma cells from autografts
   J Hematother, 5 (5), 561-2
   PubMed 8938530
7. Kvalheim G, Pharo A, Holte H, Jakobsen E, Erikstein B, Kvaløy S, Beiske K, Nesland JM, Smeland EB (1996)
   [High-dose therapy of cancer with CD34 positive cells as stem cell support]
   Tidsskr Nor Laegeforen, 116 (21), 2542-6
   PubMed 8928121
8. Kvalheim G, Wang MY, Pharo A, Holte H, Jacobsen E, Beiske K, Kvaløy S, Smeland E, Funderud S, Fodstad O (1996)
   Purging of tumor cells from leukapheresis products: experimental and clinical aspects
   J Hematother, 5 (4), 427-36
   PubMed 8877718
9. Lien HH, Holte H (1996)
   Fat replacement of Hodgkin disease of bone marrow after chemotherapy: report of three cases
   Skeletal Radiol, 25 (7), 671-4
   PubMed 8915054
10. Sletnes KE, Holte H, Halvorsen S, Jakobsen E, Wisløff F, Kvaløy S (1996)
    Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma
    Bone Marrow Transplant, 17 (4), 577-81
    PubMed 8722358
11. Waage A, Dahl IM, Evensen SA, Holte H, Lamvik J, Sletnes K, Wisløff F (1996)
    [Treatment with growth factors and cytokines in hematologic diseases]
    Tidsskr Nor Laegeforen, 116 (12), 1465-9
    PubMed 8650635

Publications 1994

1. Kavløy S, Holte H, Kvalheim G (1994)
   [High-dose autologous stem cell support in malignant diseases--an established method, uncertain indication]
   Tidsskr Nor Laegeforen, 114 (19), 2240-1
   PubMed 7992286
2. Kvalheim G, Jakobsen E, Holte H, Beiske K, Langholm R, Høiby A, Wang MY, Funderund S, Fodstad O, Smeland E (1994)
   Autologous bone marrow transplantation of non-Hodgkin's lymphoma patients with marrow purged using immunomagnetic beads
   Prog Clin Biol Res, 389, 133-8
   PubMed 7700895

Publications 1993

1. Erikstein BK, Holte H, Kvaløy S, Andersson KB, Steen HB, Hannisdal E, Smeland EB (1993)
   Expression of CD18 (integrin beta 2 chain) correlates with prognosis in malignant B cell lymphomas
   Br J Haematol, 83 (3), 392-8
   PubMed 8097923
2. Slørdahl SH, Smeland EB, Holte H, Grønn M, Lie SO, Seip M (1993)
   Leukemic blasts with markers of four cell lineages in Down's syndrome ("megakaryoblastic leukemia")
   Med Pediatr Oncol, 21 (4), 254-8
   PubMed 8469219

Publications 1992

1. Stokke T, Holte H, Smeland EB, Lie SO, Steen HB (1992)
   Differential chromatin structure-dependent binding of 7-aminoactinomycin D in normal and malignant bone marrow hematopoietic cells
   Cancer Res, 52 (18), 5007-12
   PubMed 1516056

Publications 1991

1. Alfsen GC, Beiske K, Holte H, Hovig E, Deggerdal A, Sandlie I, Widing E, Slørdahl S, Klepper LK, Sizoo W (1991)
   T-cell receptor tau delta +/CD3+4-8-T- cell acute lymphoblastic leukemias: a distinct subgroup of leukemias in children. A report of five cases
   Blood, 77 (9), 2023-30
   PubMed 1826854
2. Holte H (1991)
   [Resistance to chemotherapeutic agents in the treatment of cancer. Emphasizing the multiresistant phenotype]
   Tidsskr Nor Laegeforen, 111 (19), 2423-7
   PubMed 1926080
3. Lømo J, Smeland EB, Stokke T, Holte H, Funderud S, Blomhoff HK (1991)
   Differential effects of interferon-gamma and low molecular weight BCGF on growth of human B lymphocytes; interferon-gamma prolongs the increased c-MYC mRNA levels after activation
   Scand J Immunol, 33 (4), 365-73
   PubMed 1902001
4. Stokke T, Erikstein B, Holte H, Funderud S, Steen HB (1991)
   Cell cycle-specific expression and nuclear binding of DNA polymerase alpha
   Mol Cell Biol, 11 (6), 3384-9
   PubMed 2038340
5. Stokke T, Holte H, Erikstein B, Davies CL, Funderud S, Steen HB (1991)
   Simultaneous assessment of chromatin structure, DNA content, and antigen expression by dual wavelength excitation flow cytometry
   Cytometry, 12 (2), 172-8
   PubMed 1710961

Publications 1990

1. Abrahamsen AF, Borge L, Holte H (1990)
   Infection after splenectomy for Hodgkin's disease
   Acta Oncol, 29 (2), 167-70
   PubMed 2334569
2. Funderud S, Erikstein B, Asheim HC, Nustad K, Stokke T, Blomhoff HK, Holte H, Smeland EB (1990)
   Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation
   Eur J Immunol, 20 (1), 201-6
   PubMed 1689662
3. Smeland EB, Holte H, Kiil Blomhoff H, Asheim HC, Stokke T, Torjesen P, Funderud S (1990)
   Inhibition of polyphosphoinositide breakdown and c-myc induction accompanying inhibition of human B-cell activation by two monoclonal antibodies against the leucocyte common antigen (CD45)
   Scand J Immunol, 31 (5), 583-91
   PubMed 1693226
4. Stokke T, Holte H, Davies CD, Steen HB, Lie SO (1990)
   Quenching of Hoechst 33258 fluorescence in erythroid precursors
   Cytometry, 11 (6), 686-90
   PubMed 1696537

Publications 1989

1. Holte H, Blomhoff HK, Beiske K, Funderud S, Torjesen P, Gaudernack G, Stokke T, Smeland EB (1989)
   Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens
   Eur J Immunol, 19 (7), 1221-5
   PubMed 2547623
2. Holte H, de Lange Davies C, Beiske K, Stokke T, Marton PF, Smeland EB, Høie J, Kvaløy S (1989)
   Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma
   Int J Cancer, 44 (6), 975-80
   PubMed 2606582
3. Holte H, Stokke T, Smeland E, Watt R, Blomhoff HK, Kaalhus O, Ohlsson R (1989)
   Levels of myc protein, as analyzed by flow cytometry, correlate with cell growth potential in malignant B-cell lymphomas
   Int J Cancer, 43 (1), 164-70
   PubMed 2642893

Publications 1988

1. Beiske K, Clark EA, Holte H, Ledbetter JA, Smeland EB, Godal T (1988)
   Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets
   Int J Cancer, 42 (4), 521-8
   PubMed 2459071
2. Holte H, Torjesen P, Blomhoff HK, Ruud E, Funderud S, Smeland EB (1988)
   Cyclic AMP has the ability to influence multiple events during B cell stimulation
   Eur J Immunol, 18 (9), 1359-66
   PubMed 2458941
3. Stokke T, Holte H, Steen HB (1988)
   In vitro and in vivo activation of B-lymphocytes: a flow cytometric study of chromatin structure employing 7-aminoactinomycin D
   Cancer Res, 48 (23), 6708-14
   PubMed 3263191

Publications 1987

1. Holte H, Davies CD, Kvaløy S, Smeland EB, Foss-Abrahamsen A, Kaalhus O, Marton PF, Godal T (1987)
   The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas
   Int J Cancer, 39 (5), 590-4
   PubMed 3106247
2. Holte H, Saeter G, Dahl IM, Abrahamsen AF (1987)
   Progressive loss of vision in patients with high-grade non-Hodgkin's lymphoma
   Cancer, 60 (10), 2521-3
   PubMed 3664433
3. Lømo J, Holte H, de Lange Davies C, Ruud E, Laukas M, Smeland EB, Godal T, Blomhoff HK (1987)
   Downregulation of c-myc RNA is not a prerequisite for reduced cell proliferation, but is associated with G1 arrest in B-lymphoid cell lines
   Exp Cell Res, 172 (1), 84-91
   PubMed 3115797
4. Smeland EB, Beiske K, Ohlsson R, Holte H, Ruud E, Blomhoff HK, Jefferis R, Godal T (1987)
   Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells
   J Immunol, 138 (10), 3179-84
   PubMed 3553323
5. Smeland EB, Blomhoff HK, Holte H, Ruud E, Beiske K, Funderud S, Godal T, Ohlsson R (1987)
   Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes
   Exp Cell Res, 171 (1), 213-22
   PubMed 2442015

Publications 1986

1. Schjølseth SA, Bøhler PJ, Marton P, Holte H (1986)
   [Lymphomatoid granulomatosis]
   Tidsskr Nor Laegeforen, 106 (25), 2056-7, 2082
   PubMed 3775730